| Inserm Patent applications |
| Patent application number | Title | Published |
|---|
| 20100322913 | CHIMERIC POLYPEPTIDE COMPRISING THE FRAGMENT B OF SHIGA TOXIN AND PEPTIDES OF THERAPEUTIC INTEREST - The invention pertains to methods for using chimeric polypeptides of the formula: | 12-23-2010 |
| 20100260726 | Methods for Producing a Non Human Model for Aortic Aneurysm - The present invention relates to methods for producing a non human animal model for aortic aneurysm which could provide insight into the diagnosis and treatment of said disease. Furthermore, the present invention relates to methods and compositions for the treatment or the prevention of aneurysm in a subject in need thereof. | 10-14-2010 |
| 20090317401 | Angiogenic and immunoglobic applications of anti cd160 specific compounds obtainable from mab cl 1-r2 - The present invention relates to biological and medical application of an anti-CD160 monoclonal antibody (CL1-R2 CNCM I-3204) an of the conservative equivalents thereof. It more particularly relates to the applications of these anti-CD 160 compounds in the fields of EC angiogenesis, and NK and T cytokine production | 12-24-2009 |
| 20090186023 | ANTIBODIES DIRECTED AGAINST HEPATITIS C VIRUS E1E2 COMPLEX, COMPOSITIONS OF HCV PARTICLES, AND PHARMACEUTICAL COMPOSITIONS - New conformational antibodies are directed against HCV and more particularly to monoclonal antibodies. Described compositions of particles are liable to be recognized by the antibodies, as are pharmaceutical compositions containing them. Also described are HCV enveloped subviral particles or purified HCV enveloped complete viral particles, and the processes for preparing them. | 07-23-2009 |
| 20090131512 | Inhibition of type I in IFN production - The invention provides methods for decreasing type I IFN production by human plasmacytoid dendritic cells in response to TLR activation. | 05-21-2009 |
| 20080269188 | Oatp-C Gene C463a Polymorphism Underlies Variable Response to Statin Therapy - The present invention relates to a method for determining variable response to statin therapy in patients afflicted with or susceptible to develop cardiovascular diseases, hypercholesterolemia, Diabetes and metabolic disorders involving high baseline plasma lipid level such as high LDL-C level, comprising detecting the presence or absence of the Pro 155T hr (C463A) variant in the Organic Anion Transporting Polypeptide-C(OATP-C) gene, wherein the presence of said variant is indicative of superior response to statin therapy. It also concerns tailored treatment of different populations of patients according to the Pro155Thr (C463A) variant genotype. | 10-30-2008 |
| 20080214449 | Use of Antagonists of the Cbi Receptor For the Manufacture of a Composition Useful For the Treatment of Hepatic Diseases - The invention relates to the use of antagonists to the CB1 receptor for the preparation of a composition for the treatment of hepatic diseases and preferably to the use of N-piperidino-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methylpyrazole-3-carboxamide. | 09-04-2008 |
